Stanislas Blein
Lausanne, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Journal: Nature cancer
Published: October 09, 2023
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
Journal: Nature communications
Published: July 31, 2023
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.
Journal: The journal of allergy and clinical immunology. Global
Published: March 18, 2023
A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species.
Journal: The Journal of biological chemistry
Published: December 16, 2019
Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.
Journal: The Journal of biological chemistry
Published: February 21, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026